UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety profile of RNAi nanomedicines

Advanced drug delivery reviews, 2012-12, Vol.64 (15), p.1730-1737

2012

Volltextzugriff (PDF)

randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Proceedings of the National Academy of Sciences - PNAS, 2010-05, Vol.107 (19), p.8800-8805

2010

Volltextzugriff (PDF)

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Orphanet journal of rare diseases, 2015-09, Vol.10 (1), p.109-109, Article 109

2015

Volltextzugriff (PDF)

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate

Molecular therapy, 2017-01, Vol.25 (1), p.71-78

2017

Volltextzugriff (PDF)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

BMC neurology, 2017-09, Vol.17 (1), p.181-181, Article 181

2017

Volltextzugriff (PDF)

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

The Journal of heart and lung transplantation, 2016-02, Vol.35 (2), p.213-221

2016

Volltextzugriff (PDF)

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Nature medicine, 2023-12, Vol.29 (12), p.3127-3136

2023

Volltextzugriff (PDF)

Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study

Neurology, 2015-08, Vol.85 (8), p.675-682

2015

Volltextzugriff (PDF)

Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway

Seminars in oncology, 2006-08, Vol.33 (4), p.392-406

2006

Volltextzugriff (PDF)

RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus

American journal of respiratory and critical care medicine, 2011-02, Vol.183 (4), p.531-538

2011

Volltextzugriff (PDF)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

Orphanet journal of rare diseases, 2020-07, Vol.15 (1), p.1-179, Article 179

2020

Volltextzugriff (PDF)

Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3288-3295

2007

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer

Journal of clinical oncology, 2004-08, Vol.22 (15), p.3003-3015

2004

Volltextzugriff (PDF)

Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma

Clinical cancer research, 2006-08, Vol.12 (15), p.4619-4627

2006

Volltextzugriff (PDF)

Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells

PloS one, 2016-09, Vol.11 (9), p.e0161455-e0161455

2016

Volltextzugriff (PDF)

Decitabine Up-regulates S100A2 Expression and Synergizes with IFN-γ to Kill Uveal Melanoma Cells

Clinical cancer research, 2007-09, Vol.13 (17), p.5219-5225

2007

Volltextzugriff (PDF)

603 Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A633-A633

2021

Volltextzugriff (PDF)

Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2564-2573

2003

Volltextzugriff (PDF)

Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-γ

Cancer research (Chicago, Ill.), 2005-10, Vol.65 (19), p.8869-8877

2005

Volltextzugriff (PDF)

Sorafenib: Scientific Rationales for Single-Agent and Combination Therapy in Clear-Cell Renal Cell Carcinoma

Clinical genitourinary cancer, 2005-12, Vol.4 (3), p.167-174

Gollob, Jared A.

2005

Volltextzugriff (PDF)

Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases

Melanoma research, 2008-04, Vol.18 (2), p.147-151

2008

Volltextzugriff (PDF)

A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide, Interleukin 2, and IFN-α2B in Patients with Metastatic Melanoma

Clinical cancer research, 2002-10, Vol.8 (10), p.3075-3081

2002

Volltextzugriff (PDF)

Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response

Clinical cancer research, 2000-05, Vol.6 (5), p.1678

2000

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(92)

Publikationsform

Artikel
(109)

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Humans
(47)
Life Sciences & Biomedicine
(45)
Female
(25)
Middle Aged
(25)
Male
(24)
Adult
(22)
Aged
(17)
Biological And Medical Sciences
(17)
Medical Sciences
(16)
Oncology
(16)
Medicine, Research & Experimental
(12)
Research & Experimental Medicine
(12)
Carcinoma, Renal Cell - Drug Therapy
(11)
Immunology
(11)
Kidney Neoplasms - Drug Therapy
(11)
Melanoma - Drug Therapy
(10)
Rna Interference
(10)
Animals
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Safety profile of RNAi nanomedicines

randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study

Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway

RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer

Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer

Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma

Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells

Decitabine Up-regulates S100A2 Expression and Synergizes with IFN-γ to Kill Uveal Melanoma Cells

603 Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy

Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma

Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-γ

Sorafenib: Scientific Rationales for Single-Agent and Combination Therapy in Clear-Cell Renal Cell Carcinoma

Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases

A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide, Interleukin 2, and IFN-α2B in Patients with Metastatic Melanoma

Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response

Suchergebnisse filtern